UBS AG Increases Actavis Price Target to $237.00 (ACT)
Analysts at UBS AG increased their price objective on shares of Actavis (NYSE:ACT) from $202.00 to $237.00 in a research report issued to clients and investors on Wednesday, Analyst RN reports. The firm currently has a “buy” rating on the stock. UBS AG’s price objective points to a potential upside of 17.64% from the company’s current price.
A number of other firms have also recently commented on ACT. Analysts at Mizuho downgraded shares of Actavis from a “buy” rating to a “neutral” rating in a research note on Wednesday. They now have a $25.00 price target on the stock, down previously from $93.00. Separately, analysts at CRT Capital raised their price target on shares of Actavis from $210.00 to $230.00 in a research note on Wednesday. They now have a “buy” rating on the stock. Finally, analysts at Bank of America set a $235.00 price target on shares of Actavis in a research note on Wednesday. They now have a “buy” rating on the stock. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Actavis presently has an average rating of “Buy” and a consensus target price of $189.82.
Actavis (NYSE:ACT) traded up 4.69% during mid-day trading on Wednesday, hitting $210.92. 5,932,377 shares of the company’s stock traded hands. Actavis has a 52-week low of $82.02 and a 52-week high of $208.75. The stock’s 50-day moving average is $182.5 and its 200-day moving average is $156.7. The company’s market cap is $36.700 billion.
Actavis, Inc formerly Watson Pharmaceuticals, Inc, is a integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (NYSE:ACT) pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.